Patients with muscle-invasive urothelial cancer face a high risk of relapse despite radical surgery and chemotherapy. The immune checkpoint inhibitor pembrolizumab may reduce this risk. New ...
Joey Mattingly is an associate professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy. Stephen Morrissey, the interviewer, is the Executive Managing Editor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback